Adiposity in depression or depression in adiposity?
The role of immune-inflammatory-microbial overlap.

Oliwia Gawlik-Kotelnicka[1]

[1]Department of Affective and Psychotic Disorders,

Medical University of Lodz, Poland

Czechoslowacka Street 8/10, 92-216 Lodz, Poland

oliwia.gawlik@umed.lodz.pl.

Abstract: Metabolic disorders, metabolic syndrome and non-alcoholic fatty liver disease, and depression are those of the most common and debilitating disorders worldwide that often coexist further increasing mortality risks. Although the exact mechanisms underlying this association are poorly known, several hypotheses have been proposed: antipsychotic medication and antidepressants use, diet and physical activity or any other lifestyle factors. However, the high co-occurrence rate of depression and metabolic disorders suggests a possible pathophysiological overlap. In this paper I review several raised mechanisms for this overlap which are the hypothalamic-pituitary-adrenal axis dysregulation, immune alterations with chronic inflammation, as well as oxidative stress. In my view, there is one common thread running through all the aforementioned areas of pathophysiology which is microbiota alteration. So far, several possible interventions in our microbiota have been introduced into clinical practice - dietary and other lifestyle changes, supplementation with prebiotics or probiotics, fecal microbiota transplantation – but with vague indications. A better characterization of the above associations may represent a critical step at phenotyping, and a more targeted approach to the treatment of both depressive and metabolic disorders. At the end of the paper, I give several practical applications for future studies.

Keywords: depression, metabolic syndrome, non-alcoholic fatty liver disease, hypothalamic-pituitary-adrenal axis, inflammation, oxidative stress, microbiota

Metabolic disorders (MDs), metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD), and depression are those of the most common and debilitating disorders worldwide [1]. The one-year prevalence of depression is approximately 6% worldwide while the lifetime risk of depression (single or recurrent episode) is three times higher [2]. MetS, as a set of anthropometric, clinical and metabolic abnormalities (obesity, insulin resistance, dyslipidaemia and hypertension), has been defined different ways and some of the cut-off criteria vary considerably, thus making epidemiology studies difficult. However, the global prevalence is estimated to be about one quarter of the world population [3]. Moreover, depressive disorders (DDs) often coexist with MDs further increasing mortality risks [4,5].

A meta-analysis [6] showed that individuals with depression had 1.5 times higher odds of having MetS and prevalence of MetS in depressed subjects accounts for 30%. Moreover, very recent data from the Netherlands Study of Depression and Anxiety (NESDA) sample [7] did demonstrate that persons with atypical depression had significantly higher levels of inflammatory markers, BMI, waist circumference (WC) and triglycerides, or lower high-density lipoprotein cholesterol (HDL-C) than persons with melancholic depression. Additionally, in a large, nationally representative sample, it was found that both obesity and MetS were associated with significant depressive symptoms

independent of each other, and that participants with both conditions had the highest rate of depression as compared to the other groups [8]. Lately, it has been shown that individuals experiencing a current episode of major depressive disorder (MDD) are significantly more likely to have insulin resistance (IR) than non-depressed individuals [9]. The aforementioned liver equivalent of MetS, NAFLD, is characterized by excessive hepatic fat accumulation [10]. It is the most common cause of chronic liver disease in Western countries. Moreover, it is a multisystem disease. By analogy with MetS, a majority of deaths among IR and NAFLD patients are attributable to cardiovascular diseases (CVD) [11].

Although the exact mechanisms underlying this association are poorly known, several hypotheses have been proposed. First of all, antipsychotic medication use is associated with a significantly higher MetS prevalence. Moreover, augmentation with newer antipsychotics in non-elderly patients with depression was associated with increased mortality risk as compared to adding another antidepressant [12]. Use of antidepressants in general is uncertain [13]. Diet and physical activity accounted for 23% of the association between depression and the MetS [14]. The other factors coexisting in metabolic and depressive disorders remain poorly known. However, the high co-occurrence rate of DDs and MDs suggests a possible pathophysiological overlap. Although the precise mechanisms mediating the phenomenon have not yet been elucidated, the hypothalamic-pituitary-adrenal (HPA) axis dysregulation, immune alterations, inflammation, oxidative stress (OxS), autonomic nervous system dysregulation, IR or microbiome alterations are all interacting biological mechanisms that have been proposed [1,5,7,15–18]. It would be worth seeking for in-depth etiopathology overlap areas of the above syndromes to create new potential prophylactic or therapeutic methods. Research in this area may open door for establishing a subpopulation of patients sensitive to microbiota interventions.

To begin with, the common feature of affective and metabolic diseases is dysregulation of the HPA axis [19,20]. In depression, this axis is typically upregulated. The negative feedback of cortisol to the hypothalamus, pituitary and immune system is impaired. Excess release of cortisol into the circulatory system has a number of effects, including elevation of blood glucose, cortisol receptors desensitization leading to increased activity of the pro-inflammatory immune mediators and disturbances in neurotransmitter action [19]. However, it is worth noticing that atypical depression is associated with hypofunction rather than hyperfunction of the HPA axis, rather than a hyperfunction. In MDs, especially abdominal obesity phenotype and IR, mainly primary neuroendocrine dysregulation mechanisms are involved, as a result of genetic predisposition and altered coping with some environmental factors (stressors, lifestyle, nutrition) [20]. Final hypothalamic inflammation represents an interconnection between somatic diseases and DDs [21]. However, the exact pathophysiology of the dysregulation of the HPA axis in depression and MetS has not yet been revealed.

Inflammation in general as a response to a threat (injury/infection) is a highly beneficial process [22]. Nevertheless, a prolonged low-grade inflammatory response and systemic effects is a pathological feature [23]. It has been called chronic low-grade inflammation (CLGI) or metaflammation, and it is believed to originate, at least partially, from the abdominal adipose tissue representing a type of civilization disorder. Most modern chronic conditions may be associated with such a chronic inflammatory state which has been named Chronic Low-grade Inflammatory Phenotype (CLIP) [24]. Indeed, recent studies have confirmed that depression, anxiety and MDs are associated with CLGI. It is characterized by increased circulating pro-inflammatory cytokines like tumor necrosis factor-α (TNF-α) and interleukin-6 (Il-6) levels, altered leukocyte population frequencies in the blood, accumulation of activated immune cells in tissues, including the brain [16,25]. Although far from conclusive, emerging evidence suggests that chronic inflammatory condition in the central and peripheral immune system may mediate a subset of DD [26] commonly concurrent with obesity and metabolic diseases. This association is especially seen in atypical depression,

where subjects show increased appetite along with symptoms of depression, which then correlate with elevated serum TNF-α and CRP [7]. Moreover, it was found that depressed patients with both obesity and MetS showed the highest levels of systemic inflammation measured by CRP [8]. However, the role of specific immune cells and cytokines in the relationship between MetS and depression still remains an open issue. Moreover, research evaluating effectiveness of interventions on metabolic and inflammatory pathways should include "immuno-metabolic" form of depression [15,18].

There is also a number of studies which demonstrate that OxS (a state of imbalance between the oxidative and anti-oxidative systems of the cells and tissues which leads to the damage of cellular macromolecules) along with inflammation pave the way for the development of metabolic [27,28] as well as depressive disorders [29–32]. It includes abnormal total antioxidant capacity (TAC), antioxidants, free radicals, oxidative damage and autoimmune response products. Additionally, poorer antidepressant treatment response was shown to be related to higher levels of OxS and antidepressant response was associated with a decrease in oxidative and inflammatory markers [31,32]. Importantly, elevated OxS in MetS promoting vascular inflammation has been shown to be a major risk factor for an increased risk of CVD [27].

Elucidating these mechanisms linking MetS, depression, the HPA axis, inflammation and OxS could generate new potential therapeutic targets or patient-specific strategies aimed at combating both metabolic and depressive disorders.

Recently, there has been much interest in the role of intestinal microbiota changes in the pathophysiology of civilization diseases. The term microbiota refers to trillions of organisms present in the human body that plays a crucial role in health, including the human immune status. The gastrointestinal (GI) tract contains the densest microbial community; however, its full diversity remains uncharacterized [33,34]. It should be underlined that microbiota in non-Westernized populations is still rich while diseases of the Western civilization are connected with depletion of our microbial community [35].

The GI microbiota has been shown to be an essential part of the bidirectional and complex gut-brain axis (GBA) [36,37]. Other pathways previously established include the autonomic and the enteric nervous systems, the neuroendocrine and the immune communication. The brain influences the motor, sensory, and secretory modalities of the GI tract, whereas, the gut influences brain function, especially in areas of the brain involved to stress regulation [38]. The connection between the gut and the brain may be proved by the comorbidity between GI and neuropsychiatric diseases [39–41]. The diversity of the gut microbiota has emerged to play a significant role in the occurrence of mood and anxiety disorders [42–45]. In recent studies gut microbiota taxonomical changes were associated with the severity of depressive symptoms in clinical population [46,47]. Reduced or absent Clostridia was consistently seen in those with depression, independent of the presence of anxiety. Conversely, reduced Bacteroides may be more associated with the presence of anxiety, independent of the presence of depression. These differences suggest that gut microbiota distribution could help clarify the underlying pathology of comorbid clinical presentation [48]. Additionally, an intestinal integrity and inflammation markers were associated with the response to treatment and severity of depressive symptoms [46]. However, little is known on how microbiota health is associated with specific features of DDs.

Moreover, there is scientific data on the implication of the intestinal microbiota function in the ethiopathogenesis of MetS and the connection of dysbiosis with abdominal obesity [49,50]. Taxonomically, the relative abundance of Firmicutes and Actinobacteria in obese individuals has been described and this obesity-associated gut microbiota is able to derive more energy from food and facilitate fat storage [51]. In addition, bacteria-derived products can induce adipose tissue inflammation [52]. Gut dysbiosis can also contribute to the accumulation of fat in the liver and the pathogenesis of NAFLD, thus promoting the intestinal absorption of monosaccharides, and accelerating hepatic lipogenesis. Furthermore, the gut microbiota is involved in the regulation of NAFLD by microbial metabolites such as SCFAs

[53]. However, research results are not consistent enough. Therefore, we need more clinical studies to address the composition, function, and the role of intestinal microbiota in the prevention and treatment of MDs.

There is more and more evidence which proves that an aberrant gut microbiota may be bidirectionally connected with HPA axis disturbances [54], chronic inflammation [39,55] and OxS exacerbation in tissues [56]. Therefore, it may serve as a link between MetS, depression and dysbiosis. Indeed, the GI microbiota can activate or attenuate the HPA axis through antigens, cytokines, prostaglandins or some metabolites that cross the blood-brain barrier (BBB) [54]. Dysbiosis alters the permeability of the gut barrier, and bacterial products can increase inflammatory cytokines and alter the BBB permeability inducing neuroinflammation [55,57,58]. Dysbiosis may also promote OxS both peripherally and in the brain by interfering with the local level of radical species and with the antioxidant system [56]. Additionally, it was found that supplementation with probiotics (live microorganisms which, when consumed in adequate amounts, confer a health benefit on the host [59]) decrease inflammatory markers in healthy and various disease conditions [60,61] and restore, directly or indirectly, oxidative balance [62,63]. A better characterization of the above associations represents a critical step at phenotyping, a preface to longitudinal clinical studies, and a more targeted approach to the treatment of DDs as well as MDs (Figure 1).

Figure 1

The patophysiological overlap between depresssive disorders (DDs) and metabolic disorders (MDs).

Green: common patophysiology of civilization diseases

* co-existance of DDs and MDs;

HPA: hypothalamic-pituitary-adrenal; CLGI: chronic low-grade inflammation; OxS: oxidative stress

It should be underlined that different individuals can have taxonomically varied but functionally similar microbiota which makes functional co-assessment of microbiota health important [64]. One of potential microbial function biomarkers are SCFAs that are the most representative metabolites of fiber anaerobic fermentation. SCFAs are multi-target substances and can modify the activity of a variety of cells of the gastrointestinal, endocrine, metabolic, immune and nervous systems [65]. SCFAs are able to promote the function of the BBB and cerebral microglia, as well as increase the central expression of neurotrophic factors [66]. Interestingly, a depletion of SCFAs was reported in MDD patients [67], and their administration was shown to alleviate symptoms of depression in mice [68]. There is also some evidence that SCFAs can play an important role in regulating metabolic and cardiovascular health (reduced obesity, increased satiety factors level and improved insulin sensitivity) [53,69]. Altogether the above suggest that SCFAs may play an important role in metabolic-mood interaction although this has not yet been systematically explored.

So far, several possible interventions in our microbiotahave been made by introducing dietary and other lifestyle changes, supplementation with prebiotics (non-digestible carbohydrates that promote the growth of beneficial bacteria) or probiotics, fecal microbiota transplantation (FMT) [70,71]. Dietary fiber or fish oil intake is associated with prophylaxis and treatment efficacy in a range of diseases with CLGI as well as increased abundance of SCFA-producing bacteria. Proper diet, as an intervention targeting the microbiota, is an established way of alleviating symptoms of metabolic diseases [72], it is also perceived as an adjunctive method in the treatment of depression [73]. The

same applies to other lifestyle factors - exercise and a regular routine appear to be associated with a harmonious bacterial ecosystem [74,75]. Results of research on prebiotics suggested a decreased fasting glucose, improved insulin sensitivity and lipid profile, reduced inflammation markers and modulation of neuroinflammation [76,77]. The main ways by which probiotics may work are through modulation of the immune system, antimicrobial substances, competition against pathogenic microorganisms, enhancing the intestinal barrier function, increasing the production of anti-inflammatory molecules and antioxidants and probably several others [78]. Recent meta-analyses of reports of trials using probiotics demonstrated their possible usefulness in depressive or anxiety outcome measures [47,79,80]. It has been suggested that the microorganisms can form a new group of drugs named "psychobiotics" [81]. However, there is too little consistency among study results, especially in terms of anxiety [82–84] and strain-dependence, and there is a need to conduct research with larger groups of clinical subjects. Furthermore, it has been summarized that probiotic intake may ameliorate some of the clinical components of MetS [85–88] as well as some inflammatory biomarkers associated with the syndrome [89,90]. Similarly, an improvement in clinical features as well as in OxS biomarkers was found in patients with type 2 diabetes mellitus (DM2) [62] or polycystic ovary syndrome (PCOS) [91] after probiotic supplementation. However, discrepant data regarding the health benefits of probiotics on metabolic diseases have been reported which may partially result from the heterogeneity of therapies and protocols. Finally, there appears to be evidence for the treatment of psychiatric disorders and MetS through FMT but the data is limited [92,93]. Further research with larger sample sizes and stronger scientific design is necessary in order to fully determine the efficacy and safety of this potential treatment. Apart from that, a growing number of medications have been found to affect the gut microbiota [94]. To sum up, standardised methodology (experimental design and data analysis) in microbiota intervention trials awaits further development and precise indications as to interventions that may modulate microbiota are yet to be discovered.

Current treatments for both depression and metabolic diseases remain suboptimal for many patients making improvements and advances in the intervention options in great demand. Whilst microbiota interventions may bring benefits to some individuals who do not fully respond to antidepressant medications, the target clinical sample for this intervention is not fully recognized. For psychiatrists it is essential to cooperate not only with psychologists but also with general practitioners, dietitians and other specialists. On research ground it would be worthy creating a scientific team working on complex relationships between mental health, metabolic disorders and the microbiota-gut-brain axis. An example team would include a psychiatrist with nutritional competence, a specialist of microbiology and molecular genetics, biostatistician specializing in microbiota evaluation, as well as a consulting dietitian, an internist and a psychologist.

Targeting GI microbiota composition and metabolic functions with natural and safe compounds, such as diet, exercise, pro- or prebiotics, to promote a healthier profile may undoubtedly be a useful tool for prevention and treatment of abdominal obesity and correlated diseases in patients with depression as well as for mood symptoms improvement.

Practical applications for future studies

There are several different definitions of depression applied in clinical and research practice [95]. According to the upcoming ICD-11 depressive disorders include single episode or recurrent depressive disorder, dysthymic and mixed depressive and anxiety disorder (MDAD) (Tab. 1). The new diagnosis, underlying its impact on patients everyday functioning and quality of life, is anxious depression [96]. Additionally, the ICD-11 includes the category of MDAD because of its importance in primary care settings and because of evidence of its overlap with mood symptomatology [97]. Therefore, it would be worth incorporating the whole category of DDs as a first step of eligibility screen in studies on new potential therapeutic methods for depressive patients.

Tab. 1

Depressive disorders in ICD-11

| 6A70 Single episode depressive disorder |
| 6A71 Recurrent depressive disorder |
| 6A72 Dysthymic disorder |
| 6A73 Mixed depressive and anxiety disorder |
| 6A7Y Other specified depressive disorders |
| 6A7Z Depressive disorders, unspecified |

It is now agreed that in the case of MetS the criteria set by the International Diabetes Federation (IDF; Tab. 2) remains the most useful and widely accepted description of this cluster of metabolically related cardiovascular risk factors which also predict a high risk of developing diabetes (if not already present). The IDF definition and criteria address both clinical and research needs, providing a tool suitable for worldwide use [98]. In addition, the application of non-invasive markers of NAFLD, APRI and FIB-4 scores, to prognosticate liver dysfunction in this group of patients seems valuable in terms of stratifying patients and searching for biomarkers of a subpopulation sensitive to specific treatment. FIB-4 and APRI have demonstrated ability to risk stratify patients for liver-related morbidity and mortality, with comparable performance to a liver biopsy [99].

Tab. 2

The International Diabetes Federation (IDF) criteria of MetS

- Central obesity
  (defined as waist circumference* with ethnicity specific values; for Caucasian race: Male≥ 94 cm Female≥ 80 cm);

  * If BMI is >30kg/m², central obesity can be assumed, and waist circumference does not need to be measured

plus any two of the following four factors:

- Raised triglycerides ≥ 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality
- Reduced HDL cholesterol < 40 mg/dL (1.03 mmol/L) in males, < 50 mg/dL (1.29 mmol/L) in females or specific treatment for this lipid abnormality
- Raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of previously diagnosed hypertension
- Raised fasting plasma glucose ≥ 5.6 mmol/l (100 mg/dl) or previously diagnosed type 2 diabetes

In terms of HPA axis abnormalities, CLGI, OxS and intestinal dysbiosis and according to the available data, it appears that there is no single marker to detect subtle alterations of these systems in depressive or metabolic diseases. On the contrary, the data indicate the need for multiple parameters. It might be useful to combine all endocrine,

inflammatory and microbiotic parameters to successfully predict this multidirectional complex leading to many years in disability or premature death.

In conclusion, it seems worth assessing the intestinal microbiota function and composition, HPA axis function indicators, CLGI markers or OxS parameters as potential bioindicators of depressive subpopulation sensitive to add-on treatment with microbiota interventions. Such a trial, if successful, could establish easy-to-use biomarkers for clinical practice. Given the personal and societal cost of treatment of civilization diseases, the research would contribute to advancement in health care over millions of people.

Funding

This research received no external funding.

Conflicts of Interest

The author declares no conflict of interest.

References

1. Marazziti D, Rutigliano G, Baroni S, Landi P, Dell'Osso L. Metabolic syndrome and major depression. *CNS Spectr*. 2014;19(4):293-304. doi:10.1017/S1092852913000667

2. Malhi GS, Mann JJ. Depression. *Lancet*. 2018;392(10161):2299-2312. doi:10.1016/S0140-6736(18)31948-2

3. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. *Curr Hypertens Rep*. 2018;20(2). doi:10.1007/s11906-018-0812-z

4. Shinkov A, Borissova AM, Kovatcheva R, et al. Increased prevalence of depression and anxiety among subjects with metabolic syndrome and known type 2 diabetes mellitus–a population-based study. *Postgrad Med*. 2018;130(2):251-257. doi:10.1080/00325481.2018.1410054

5. Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: Overview, mechanisms, and implications. *Dialogues Clin Neurosci*. 2018;20(1):63-73.

6. Vancampfort D, Correll CU, Wampers M, et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: A meta-analysis of prevalences and moderating variables. *Psychol Med*. 2014;44(10):2017-2028. doi:10.1017/S0033291713002778

7. Lamers F, Milaneschi Y, De Jonge P, Giltay EJ, Penninx BWJH. Metabolic and inflammatory markers: Associations with individual depressive symptoms. *Psychol Med*. 2018;48(7):1102-1110. doi:10.1017/S0033291717002483

8. Moazzami K, Lima BB, Sullivan S, Shah A, Bremner JD, Vaccarino V. Independent and Joint Association of Obesity and Metabolic Syndrome with Depression and Inflammation. *Heal Psychol*. 2019;38(7):586-595. doi:10.1037/hea0000764

9. Watson KT, Simard JF, Henderson VW, et al. Association of Insulin Resistance With Depression Severity and Remission Status. *JAMA Psychiatry*. December 2020. doi:10.1001/jamapsychiatry.2020.3669

10. Byrne CD, Targher G. NAFLD: A multisystem disease. *J Hepatol*. 2015;62(S1):S47-S64. doi:10.1016/j.jhep.2014.12.012

11. Jennings J, Faselis C, Yao MD. NAFLD-NASH: An Under-Recognized Epidemic. *Curr Vasc Pharmacol*. 2017;16(3):209-213. doi:10.2174/1570161115666170622074007

12. Gerhard T, Stroup TS, Correll CU, et al. Mortality risk of antipsychotic augmentation for adult depression. Wright JM, ed. *PLoS One*. 2020;15(9):e0239206. doi:10.1371/journal.pone.0239206

13. McIntyre RS, Park KY, Law CWY, et al. The association between conventional antidepressants and the metabolic syndrome: A review of the evidence and clinical implications. *CNS Drugs*. 2010;24(9):741-753. doi:10.2165/11533280-000000000-00000

14. Matta J, Hoertel N, Kesse-Guyot E, et al. Diet and physical activity in the association between depression and metabolic syndrome: Constances study. *J Affect Disord*. 2019;244:25-32. doi:10.1016/j.jad.2018.09.072

15. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"? *Ann Clin Psychiatry*. 2007;19(4):257-264. doi:10.1080/10401230701653377

16. Chan KL, Cathomas F, Russo SJ. Central and peripheral inflammation link metabolic syndrome and major depressive

disorder. *Physiology*. 2019;34(2):123-133. doi:10.1152/physiol.00047.2018

17. Farzi A, Hassan AM, Zenz G, Holzer P. Diabesity and mood disorders: Multiple links through the microbiota-gut-brain axis. *Mol Aspects Med*. 2019;66:80-93. doi:10.1016/j.mam.2018.11.003

18. Lamers F, Milaneschi Y, Vinkers CH, Schoevers RA, Giltay EJ, Penninx BWJH. Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA study. *Brain Behav Immun*. 2020;88:174-183. doi:10.1016/j.bbi.2020.04.002

19. Van Den Eede F, Claes SJ. Mechanisms of depression: Role of the HPA axis. *Drug Discov Today Dis Mech*. 2004;1(4):413-418. doi:10.1016/j.ddmec.2004.11.021

20. Pasquali R, Vicennati V, Cacciari M, Pagotto U. The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. In: *Annals of the New York Academy of Sciences*. Vol 1083. Blackwell Publishing Inc.; 2006:111-128. doi:10.1196/annals.1367.009

21. Cernackova A, Durackova Z, Trebaticka J, Mravec B. Neuroinflammation and depressive disorder: The role of the hypothalamus. *J Clin Neurosci*. 2020;75:5-10. doi:10.1016/j.jocn.2020.03.005

22. Medzhitov R. Origin and physiological roles of inflammation. *Nature*. 2008;454(7203):428-435. doi:10.1038/nature07201

23. Margioris AN, Dermitzaki E, Venihaki M, Tsatsanis C. Chronic low-grade inflammation. In: *Diet, Immunity and Inflammation*. Elsevier Ltd.; 2013:105-120. doi:10.1533/9780857095749.1.105

24. Chen Y, Liu S, Leng SX. Chronic Low-grade Inflammatory Phenotype (CLIP) and Senescent Immune Dysregulation. *Clin Ther*. 2019;41(3):400-409. doi:10.1016/j.clinthera.2019.02.001

25. Bremmer MA, Beekman ATF, Deeg DJH, et al. Inflammatory markers in late-life depression: Results from a population-based study. *J Affect Disord*. 2008;106(3):249-255. doi:10.1016/j.jad.2007.07.002

26. Leonard BE. Inflammation and depression: A causal or coincidental link to the pathophysiology? *Acta Neuropsychiatr*. 2018;30(1):1-16. doi:10.1017/neu.2016.69

27. Vona R, Gambardella L, Cittadini C, Straface E, Pietraforte D. Biomarkers of Oxidative Stress in Metabolic Syndrome and Associated Diseases. *Oxid Med Cell Longev*. 2019;2019:8267234. doi:10.1155/2019/8267234

28. Carrier A. Metabolic Syndrome and Oxidative Stress: A Complex Relationship. *Antioxid Redox Signal*. 2017;26(9):429-431. doi:10.1089/ars.2016.6929

29. Black CN, Bot M, Scheffer PG, Cuijpers P, Penninx BWJH. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. *Psychoneuroendocrinology*. 2015;51:164-175. doi:10.1016/j.psyneuen.2014.09.025

30. Rani V, Deep G, Singh RK, Palle K, Yadav UCS. Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. *Life Sci*. 2016;148:183-193. doi:10.1016/j.lfs.2016.02.002

31. Liu T, Zhong S, Liao X, et al. A meta-analysis of oxidative stress markers in depression. *PLoS One*. 2015;10(10). doi:10.1371/journal.pone.0138904

32. Lindqvist D, Dhabhar FS, James SJ, et al. Oxidative stress, inflammation and treatment response in major depression. *Psychoneuroendocrinology*. 2017;76:197-205. doi:10.1016/j.psyneuen.2016.11.031

33. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. *Nature*. 2012;489(7415):220-230. doi:10.1038/nature11550

34. Pasolli E, Asnicar F, Manara S, et al. Extensive Unexplored Human Microbiome Diversity Revealed by Over 150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle. *Cell*. 2019;176(3):649-662.e20. doi:10.1016/j.cell.2019.01.001

35. Salvucci E. The disappearing microbiota: Diseases of the Western civilization. In: *How Fermented Foods Feed a Healthy Gut Microbiota: A Nutrition Continuum*. Springer International Publishing; 2019:325-347. doi:10.1007/978-3-030-28737-5_14

36. Skonieczna-Żydecka K, Marlicz W, Misera A, Koulaouzidis A, Łoniewski I. Microbiome—The Missing Link in the Gut-Brain Axis: Focus on Its Role in Gastrointestinal and Mental Health. *J Clin Med*. 2018;7(12):521. doi:10.3390/jcm7120521

37. Dinan TG, Cryan JF. The Microbiome-Gut-Brain Axis in Health and Disease. *Gastroenterol Clin North Am*. 2017;46(1):77-89.

doi:10.1016/j.gtc.2016.09.007

38.   Kelly JR, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbiota axis: challenges for translation in psychiatry. *Ann Epidemiol*. 2016;26(5):366-372. doi:10.1016/j.annepidem.2016.02.008

39.   Carlessi AS, Borba LA, Zugno AI, Quevedo J, Réus GZ. Gut microbiota–brain axis in depression: The role of neuroinflammation. *Eur J Neurosci*. 2019. doi:10.1111/ejn.14631

40.   Gulas E, Wysiadecki G, Strzelecki D, Gawlik-Kotelnicka O, Polguj M. Can microbiology affect psychiatry? A link between gut microbiota and psychiatric disorders. *Psychiatr Pol*. 2018;52(6). doi:10.12740/PP/OnlineFirst/81103

41.   Liu Y, Zhang L, Wang X, et al. Similar Fecal Microbiota Signatures in Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression. *Clin Gastroenterol Hepatol*. 2016;14(11):1602-1611.e5. doi:10.1016/j.cgh.2016.05.033

42.   Lach G, Schellekens H, Dinan TG, Cryan JF. Anxiety, Depression, and the Microbiome: A Role for Gut Peptides. *Neurotherapeutics*. 2018;15(1):36-59. doi:10.1007/s13311-017-0585-0

43.   Aizawa E, Tsuji H, Asahara T, et al. Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder. *J Affect Disord*. 2016;202:254-257. doi:10.1016/j.jad.2016.05.038

44.   Zheng P, Zeng B, Zhou C, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. *Mol Psychiatry*. 2016;21(6):786-796. doi:10.1038/mp.2016.44

45.   Naseribafrouei A, Hestad K, Avershina E, et al. Correlation between the human fecal microbiota and depression. *Neurogastroenterol Motil*. 2014;26(8):1155-1162. doi:10.1111/nmo.12378

46.   Liśkiewicz P, Kaczmarczyk M, Misiak B, et al. Analysis of gut microbiota and intestinal integrity markers of inpatients with major depressive disorder. *Prog Neuro-Psychopharmacology Biol Psychiatry*. August 2020:110076. doi:10.1016/j.pnpbp.2020.110076

47.   Sanada K, Nakajima S, Kurokawa S, et al. Gut microbiota and majore depressive disorder: A systematic review and meta-analysis. *J Affect Disord*. 2020. doi:10.1016/j.jad.2020.01.102

48.   Mason BL, Li Q, Minhajuddin A, et al. Reduced anti-inflammatory gut microbiota are associated with depression and anhedonia. *J Affect Disord*. 2020;266:394-401. doi:10.1016/j.jad.2020.01.137

49.   Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. *J Clin Invest*. 2019;129(10):4050-4057. doi:10.1172/JCI129194

50.   Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. *Nature*. 2009;457(7228):480-484. doi:10.1038/nature07540

51.   Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature*. 2006;444(7122):1027-1031. doi:10.1038/nature05414

52.   Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives. *Curr Obes Rep*. 2019;8(3):317-332. doi:10.1007/s13679-019-00352-2

53.   Dai X, Hou H, Zhang W, et al. Microbial Metabolites: Critical Regulators in NAFLD. *Front Microbiol*. 2020;11. doi:10.3389/fmicb.2020.567654

54.   Misiak B, Łoniewski I, Marlicz W, et al. The HPA axis dysregulation in severe mental illness: Can we shift the blame to gut microbiota? *Prog Neuro-Psychopharmacology Biol Psychiatry*. 2020;102. doi:10.1016/j.pnpbp.2020.109951

55.   Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell*. 2014;157(1):121-141. doi:10.1016/j.cell.2014.03.011

56.   L D, I P-O, L C, et al. Oxidative Stress and the Microbiota-Gut-Brain Axis. *Oxid Med Cell Longev*. 2018;2018. doi:10.1155/2018/2406594

57.   Dam B, Misra A, Banerjee S. Role of gut microbiota in combating oxidative stress. In: *Oxidative Stress in Microbial Diseases*. Springer Singapore; 2019:43-82. doi:10.1007/978-981-13-8763-0_4

58.   Koopman M, Daniels JK, Spitzer C, Lampe A, El Aidy S. Depressed gut? the microbiota-diet-inflammation trialogue in

depression. *Curr Opin Psychiatry*. 2017;30(5):369-377. doi:10.1097/YCO.0000000000000350

59. Hill C, Guarner F, Reid G, et al. Expert consensus document: The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol*. 2014;11(8):506-514. doi:10.1038/nrgastro.2014.66

60. Kazemi A, Soltani S, Ghorabi S, et al. Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials. *Clin Nutr*. 2019. doi:10.1016/j.clnu.2019.04.004

61. Custodero C, Mankowski RT, Lee SA, et al. Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis. *Ageing Res Rev*. 2018;46:42-59. doi:10.1016/j.arr.2018.05.004

62. Ardeshirlarijani E, Tabatabaei-Malazy O, Mohseni S, Qorbani M, Larijani B, Baradar Jalili R. Effect of probiotics supplementation on glucose and oxidative stress in type 2 diabetes mellitus: a meta-analysis of randomized trials. *DARU, J Pharm Sci*. 2019;27(2):827-837. doi:10.1007/s40199-019-00302-2

63. Ballini A, Santacroce L, Cantore S, et al. Probiotics Efficacy on Oxidative Stress Values in Inflammatory Bowel Disease: A Randomized Double-Blinded Placebo-Controlled Pilot Study. *Endocrine, Metab Immune Disord - Drug Targets*. 2018;19(3):373-381. doi:10.2174/1871530319666181221150352

64. Cheung SG, Goldenthal AR, Uhlemann AC, Mann JJ, Miller JM, Sublette ME. Systematic review of gut microbiota and major depression. *Front Psychiatry*. 2019;10(FEB). doi:10.3389/fpsyt.2019.00034

65. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The Role of Short-Chain Fatty Acids in Health and Disease. In: ; 2014:91-119. doi:10.1016/B978-0-12-800100-4.00003-9

66. Valvassori S, Varela R, Arent C, et al. Sodium Butyrate Functions as an Antidepressant and Improves Cognition with Enhanced Neurotrophic Expression in Models of Maternal Deprivation and Chronic Mild Stress. *Curr Neurovasc Res*. 2014;11(4):359-366. doi:10.2174/1567202611666140829162158

67. Skonieczna-żydecka K, Grochans E, Maciejewska D, et al. Faecal short chain fatty acids profile is changed in Polish depressive women. *Nutrients*. 2018;10(12). doi:10.3390/nu10121939

68. Yamawaki Y, Yoshioka N, Nozaki K, et al. Sodium butyrate abolishes lipopolysaccharide-induced depression-like behaviors and hippocampal microglial activation in mice. *Brain Res*. 2018;1680:13-38. doi:10.1016/j.brainres.2017.12.004

69. Chambers ES, Preston T, Frost G, Morrison DJ. Role of Gut Microbiota-Generated Short-Chain Fatty Acids in Metabolic and Cardiovascular Health. *Curr Nutr Rep*. 2018;7(4):198-206. doi:10.1007/s13668-018-0248-8

70. Quigley EMM, Gajula P. Recent advances in modulating the microbiome. *F1000Research*. 2020;9:46. doi:10.12688/f1000research.20204.1

71. Zmora N, Suez J, Elinav E. You are what you eat: diet, health and the gut microbiota. *Nat Rev Gastroenterol Hepatol*. 2019;16(1):35-56. doi:10.1038/s41575-018-0061-2

72. Velasquez MT. Altered gut microbiota: A link between diet and the metabolic syndrome. *Metab Syndr Relat Disord*. 2018;16(7):321-328. doi:10.1089/met.2017.0163

73. Marx W, Lane M, Hockey M, et al. Diet and depression: exploring the biological mechanisms of action. *Mol Psychiatry*. November 2020. doi:10.1038/s41380-020-00925-x

74. J F, M S, RE W, et al. A meta-review of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. *World Psychiatry*. 2020;19(3). doi:10.1002/WPS.20773

75. Panasevich MR, Peppler WT, Oerther DB, Wright DC, Rector RS. Microbiome and NAFLD: Potential influence of aerobic fitness and lifestyle modification. *Physiol Genomics*. 2017;49(8):385-399. doi:10.1152/physiolgenomics.00012.2017

76. Barengolts E. Gut microbiota, prebiotics, probiotics, and synbiotics in management of obesity and prediabetes: Review of randomized controlled trials. *Endocr Pract*. 2016;22(10):1224-1234. doi:10.4158/EP151157.RA

77. Paiva IHR, Duarte-Silva E, Peixoto CA. The role of prebiotics in cognition, anxiety, and depression. *Eur Neuropsychopharmacol*. 2020;34:1-18. doi:10.1016/j.euroneuro.2020.03.006

78.   Aponte M, Murru N, Shoukat M. Therapeutic, Prophylactic, and Functional Use of Probiotics: A Current Perspective. *Front Microbiol*. 2020;11. doi:10.3389/fmicb.2020.562048

79.   Huang R, Wang K, Hu J. Effect of probiotics on depression: A systematic review and meta-analysis of randomized controlled trials. *Nutrients*. 2016;8(8). doi:10.3390/nu8080483

80.   Ng QX, Peters C, Ho CYX, Lim DY, Yeo WS. A meta-analysis of the use of probiotics to alleviate depressive symptoms. *J Affect Disord*. 2018;228:13-19. doi:10.1016/j.jad.2017.11.063

81.   Dinan TG, Stanton C, Cryan JF. Psychobiotics: A novel class of psychotropic. *Biol Psychiatry*. 2013;74(10):720-726. doi:10.1016/j.biopsych.2013.05.001

82.   A H. Probiotics Supplementation in Prophylaxis and Treatment of Depressive and Anxiety Disorders - A Review of Current Research. *Psychiatr Pol*. 2019;53(2).

83.   Slykerman RF, Hood F, Wickens K, et al. Effect of Lactobacillus rhamnosus HN001 in Pregnancy on Postpartum Symptoms of Depression and Anxiety: A Randomised Double-blind Placebo-controlled Trial. *EBioMedicine*. 2017;24:159-165. doi:10.1016/j.ebiom.2017.09.013

84.   Liu RT, Walsh RFL, Sheehan AE. Prebiotics and probiotics for depression and anxiety: A systematic review and meta-analysis of controlled clinical trials. *Neurosci Biobehav Rev*. 2019;102:13-23. doi:10.1016/j.neubiorev.2019.03.023

85.   Sáez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, Gil A. Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: A review of human clinical trials. *Int J Mol Sci*. 2016;17(6). doi:10.3390/ijms17060928

86.   Szulińska M, Łoniewski I, van Hemert S, Sobieska M, Bogdański P. Dose-dependent effects of multispecies probiotic supplementation on the lipopolysaccharide (LPS) level and cardiometabolic profile in obese postmenopausal women: A 12-week randomized clinical trial. *Nutrients*. 2018;10(6). doi:10.3390/nu10060773

87.   Dong Y, Xu M, Chen L, Bhochhibhoya A. Probiotic Foods and Supplements Interventions for Metabolic Syndromes: A Systematic Review and Meta-Analysis of Recent Clinical Trials. *Ann Nutr Metab*. 2019;74(3):224-241. doi:10.1159/000499028

88.   Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: A systematic review and meta-analysis of randomised controlled trials. *BMJ Open*. 2019;9(3). doi:10.1136/bmjopen-2017-017995

89.   Tenorio-Jiménez C, Martínez-Ramírez MJ, Gil Á, Gómez-Llorente C. Effects of probiotics on metabolic syndrome: A systematic review of randomized clinical trials. *Nutrients*. 2020;12(1). doi:10.3390/nu12010124

90.   Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. *Clin Nutr*. 2019. doi:10.1016/j.clnu.2018.04.010

91.   Tabrizi R, Ostadmohammadi V, Akbari M, et al. The Effects of Probiotic Supplementation on Clinical Symptom, Weight Loss, Glycemic Control, Lipid and Hormonal Profiles, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials. *Probiotics Antimicrob Proteins*. 2019. doi:10.1007/s12602-019-09559-0

92.   Chinna Meyyappan A, Forth E, Wallace CJK, Milev R. Effect of fecal microbiota transplant on symptoms of psychiatric disorders: A systematic review. *BMC Psychiatry*. 2020;20(1). doi:10.1186/s12888-020-02654-5

93.   Proença IM, Allegretti JR, Bernardo WM, et al. Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials. *Nutr Res*. 2020;83:1-14. doi:10.1016/j.nutres.2020.06.018

94.   Vich Vila A, Collij V, Sanna S, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. *Nat Commun*. 2020;11(1). doi:10.1038/s41467-019-14177-z

95.   Sjöberg L, Karlsson B, Atti AR, Skoog I, Fratiglioni L, Wang HX. Prevalence of depression: Comparisons of different depression definitions in population-based samples of older adults. *J Affect Disord*. 2017;221:123-131.

doi:10.1016/j.jad.2017.06.011

96.   Reed GM, First MB, Kogan CS, et al. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. *World Psychiatry*. 2019;18(1):3-19. doi:10.1002/wps.20611

97.   Ziebold C, Goldberg DP, Reed GM, et al. Dimensional analysis of depressive, anxious and somatic symptoms presented by primary care patients and their relationship with ICD-11 PHC proposed diagnoses. *Psychol Med*. 2019;49(5):764-771. doi:10.1017/S0033291718001381

98.   Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome - A new world-wide definition. A consensus statement from the International Diabetes Federation. *Diabet Med*. 2006;23(5):469-480. doi:10.1111/j.1464-5491.2006.01858.x

99.   Lee J, Vali Y, Boursier J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score, and APRI for NAFLD-related events: a systematic review. *Liver Int*. September 2020. doi:10.1111/liv.14669